Physalaemin

An oligopeptide isolated from the skin of Physalaemus fuscumaculatus, a South American frog. It is a typical kinin, resembling SUBSTANCE P in structure and action and has been proposed as a sialagogue, antihypertensive, and vasodilator.

Also Known As:

Networked: 11 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Chromosome Aberrations (Chromosome Abnormalities) 06/01/1990 - "The major progress in our understanding of SCLC includes: 1) the availability of nonspecific biological tumour markers such as neuron-specific enolase (NSE), the BB isoenzyme of creatine phosphokinase (CPKBB), bombesin/gastrin releasing peptide (GRP) and chromogranin A; 2) the generation of monoclonal antibodies raised against the neural and epithelial features of SCLC tumours; 3) the identification of several autocrine growth factors such as bombesin/GRP, insulin-like growth factor (IGF), transferrin and physalaemin; 4) the close study of cytogenetic abnormalities leading to the discovery of a unique chromosomal deletion of the short arm of chromosome 3 (del 3p 14-21), and to changes in oncogenic expression, e.g. "
2.	Small Cell Carcinoma 01/01/1985 - "Physalaemin-like immunoreactivity from human lung small cell carcinoma: isocratic reversed-phase HPLC analysis of the chemically modified peptide." 01/07/1983 - "These data suggest that small-cell carcinoma of the lung contains a physalaemin-like peptide that has structural and biological homology to its amphibian counterpart." 01/07/1983 - "Immunoreactivity to the amphibian peptide physalaemin was characterized from extracts of a human lung small-cell carcinoma by immunological, chemical, and pharmacological means. " 01/07/1983 - "Physalaemin: an amphibian tachykinin in human lung small-cell carcinoma."
3.	Neoplasms (Cancer) 01/07/1983 - "Both physalaemin and the tumor peptide produced a contractile response of isolated guinea pig ileum at threshold concentrations of approximately 100 to 150 picograms per milliliter. " 01/07/1983 - "Tumor-related peptide cross-reacted with three antiserums to physalaemin to yield 1.1 to 1.6 nanomoles per gram of tissue. " 02/01/1994 - "In contrast, TNT-1/IL-1 and TNT-1/TNF produced a combination of effects, and TNT-1/leukotriene B4, TNT-1/bradykinin, and TNT-1/physalaemin affected only tumor blood volume. " 02/01/1994 - "TNT-1/IL-2 gave the highest percent injected dose/g in tumor (4.80), compared with TNT-1/TNF (4.00), TNT-1/IL-1 (3.83), TNT-1/leukotriene-B4 (2.84), TNT-1/histamine (2.80), TNT-1/physalaemin (2.19), TNT-1/bradykinin (1.57), or TNT-1 alone (1.28). " 01/07/1983 - "Physalaemin and tumor peptide had similar retention times on high-performance liquid chromatography after chemical and enzymic modifications that included pH changes, oxone oxidation, use of a hydrophilic ion-pairing reagent, and digestion with trypsin and pyroglutamate aminopeptidase. "
4.	Carcinoid Tumor (Carcinoid) 06/01/1985 - "Chemical and immunochemical characterisation of substance P-like immunoreactivity and physalaemin-like immunoreactivity in a carcinoid tumour." 09/01/1986 - "In addition, the plasma concentration of tachykinin [TKLI(K12)], using an assay that detects NKA, NPK, kassinin, eledoisin, and NKB, but not substance P and physalaemin, and the urinary excretion of 5-hydroxyindole acetic acid (5-HIAA) were measured in 20 patients with midgut carcinoid tumors before and during treatment with human leucocyte interferon. "
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 05/01/1987 - "In vitro growth inhibition of human small cell lung cancer by physalaemin."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Chromogranin A
3.	Intercellular Signaling Peptides and Proteins (Growth Factors)
4.	Gastrin-Releasing Peptide
5.	Transferrin (beta 2 Transferrin)
6.	Phosphopyruvate Hydratase (Enolase)
7.	Isoenzymes
8.	Creatine Kinase (Creatine Phosphokinase)
9.	Bombesin
10.	Insulin-Like Peptides